Tetraarsenic oxide-induced inhibition of malignant glioma cell invasion in vitro via a decrease in matrix

Ho-Shin Gwak1, Myung-Jin Park, In-Chul Park

  • 1Neuro-Oncology Clinic, National Cancer Center, Goyang;

Journal of Neurosurgery
|October 11, 2014
PubMed
Abstract

Insights

Tetraarsenic oxide (TAO) inhibits malignant glioma cell proliferation and invasiveness by reducing MMP-2, MT1-MMP, and Akt phosphorylation. This study explores TAO

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Malignant glioma's local invasiveness hinders treatment efficacy.
  • Tetraarsenic oxide (TAO) shows potential anticancer effects at lower concentrations than arsenic trioxide (ATO).
  • TAO's anti-invasive properties and cytotoxic concentration in glioma require elucidation.

Purpose of the Study:

  • Determine the cytotoxic concentration of TAO in malignant glioma cell lines.
  • Investigate TAO's anti-invasive effects independent of cell death.
  • Assess TAO's impact on matrix metalloproteinase (MMP) and Akt signaling pathways.

Main Methods:

  • Cultured PTEN-deficient (U87MG, U251MG, U373MG) and PTEN-functional (LN428) glioma cells with varying TAO concentrations.
  • Analyzed cell invasiveness, MMP secretion (gelatin zymography), MT1-MMP expression (Western blot), and Akt activity (kinase assay, Western blot).

Main Results:

  • TAO inhibited 50% of glioma cell proliferation at 6.3-12.2 μM.
  • TAO significantly reduced cell invasiveness, MMP-2 activity, and MT1-MMP expression in a dose-dependent manner.
  • TAO inhibited Akt phosphorylation and kinase activity irrespective of PTEN status.

Conclusions:

  • TAO effectively inhibits glioblastoma cell proliferation and invasiveness.
  • TAO's anti-invasive mechanism involves decreased MMP-2 secretion, MT1-MMP expression, and Akt phosphorylation, independent of cytotoxicity.
  • Further in vivo studies are warranted to explore TAO's therapeutic potential as an anti-invasive agent.

Related Concept Videos